E. Borazanci, C. V. Dang, and R. W. Robey, A Riddle Wrapped in a Mystery inside an Enigma, Clin Cancer Res, vol.23, issue.7, pp.1629-1637, 2017.

V. Mahadevan, Anatomy of the pancreas and spleen, Surgery (Oxford), vol.37, issue.6, pp.297-301, 2019.

, Terese Winslow LLC Medical Illustration, pour le National Cancer Institute, 2009.

N. Bardeesy and R. A. Depinho, Pancreatic cancer biology and genetics, Nat Rev Cancer, vol.2, issue.12, pp.897-909, 2002.

S. J. Pandol, The Exocrine Pancreas, Morgan & Claypool Life Sciences; 2010. Digestive Enzymes

D. Longnecker, Anatomy and Histology of the Pancreas. Pancreapedia: Exocrine Pancreas Knowledge Base, 2014.

D. G. Baskin, A Historical Perspective on the Identification of Cell Types in Pancreatic Islets of Langerhans by Staining and Histochemical Techniques, J Histochem Cytochem, vol.63, issue.8, pp.543-558, 2015.

, American Gastroenterological Association. Cross section of the upper abdomen at the level of the pancreas

, International Classification of Diseases for Oncology, Institut National du Cancer. Classification des cancers Disponible

D. Hanahan and R. A. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-674, 2011.

, Cancers et tumeurs du pancréas, 2019.

, National Cancer Institute, Pancreas Stats, 2013.

A. Drouillard, S. Manfredi, and C. Lepage, Épidémiologie du cancer du pancréas, Bulletin du Cancer, vol.105, issue.1, pp.63-69, 2018.

J. He, B. H. Edil, and J. L. Cameron, Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts, J Gastrointest Surg, vol.17, issue.2, pp.339-344, 2013.

S. Solomon, S. Das, and R. Brand, Inherited Pancreatic Cancer Syndromes, Cancer J, vol.18, issue.6, pp.485-491, 2012.

K. A. Brune, B. Lau, and E. Palmisano, Importance of age of onset in pancreatic cancer kindreds, JNCI, vol.102, pp.119-126, 2010.

A. P. Klein, Genetic Susceptibility to Pancreatic Cancer, Mol Carcinog, vol.51, issue.1, pp.14-24, 2012.

S. Dindyal and D. Spalding, Pancreatic cancer Medicine, vol.47, issue.7, pp.433-439, 2019.

A. B. Lowenfels, P. Maisonneuve, and G. Cavallini, Pancreatitis and the Risk of Pancreatic Cancer, NEJM, vol.328, issue.20, pp.1433-1437, 1993.

A. B. Lowenfels and P. Maisonneuve, Epidemiology and risk factors for pancreatic cancer, Best Pract Res Clin Gastroenterol, vol.20, issue.2, pp.197-209, 2006.

A. Drouillard, S. Manfredi, and C. Lepage, Épidémiologie du cancer du pancréas, Bulletin du Cancer, vol.105, issue.1, pp.63-69, 2018.

V. Bagnardi, M. Rota, and E. Botteri, Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis, Br J Cancer, vol.112, pp.580-93, 2015.

R. Huxley, A. Ansary-moghaddam, B. De-gonzález, and A. , Type-II diabetes and pancreatic cancer : A meta-analysis of 36 studies, Br J Cancer, vol.92, pp.2076-83, 2005.

S. Jones, X. Zhang, and D. W. Parsons, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, vol.321, issue.5897, pp.1801-1806, 2008.

N. Bardeesy and R. A. Depinho, Pancreatic cancer biology and genetics, Nat Rev Cancer, vol.2, issue.12, pp.897-909, 2002.

J. P. Morris, S. C. Wang, M. Hebrok, . Kras, and . Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma, Nat Rev Cancer, vol.10, issue.10, pp.683-695, 2010.

N. Suehara, K. Mizumoto, and T. Muta, Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states, Clin Cancer Res, vol.3, issue.6, pp.993-998, 1997.

J. Y. Yun, C. Rago, and I. Cheong, Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells, Science, vol.325, issue.5947, pp.1555-1559, 2009.

. Adapté-de-devita and R. Hellman, Principles & practice of oncology 11th Edition, 2018.

S. Yachida, S. Jones, and I. Bozic, Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer, Nature, vol.467, issue.7319, pp.1114-1117, 2010.

N. Bardeesy and R. A. Depinho, Pancreatic cancer biology and genetics, Nat Rev Cancer, vol.2, issue.12, pp.897-909, 2002.

A. Neesse, P. Michl, and K. K. Frese, Stromal biology and therapy in pancreatic cancer, Gut, vol.60, issue.6, pp.861-868, 2011.

V. T. Devita, T. S. Lawrence, S. A. Rosenberg, and H. Devita, Rosenberg Principles & practice of oncology 11th Edition, 2018.

M. Orth, P. Metzger, and S. Gerum, Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches, Radiat Oncol, vol.14, issue.1, p.141, 2019.

M. Nielsen, M. B. Mortensen, and S. Detlefsen, Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells, World J Gastroenterol, vol.22, issue.9, pp.2678-2700, 2016.

K. Izuishi, K. Kato, and T. Ogura, Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy, Cancer research, vol.60, issue.21, pp.6201-6207, 2000.

A. F. Hezel, A. C. Kimmelman, and B. Z. Stanger, Genetics and biology of pancreatic ductal adenocarcinoma, Genes Dev, vol.20, issue.10, pp.1218-1249, 2006.

B. Ren, M. Cui, and G. Yang, Tumor microenvironment participates in metastasis of pancreatic cancer, Mol Cancer, vol.17, 2018.

S. T. Chari, K. Kelly, and M. A. Hollingsworth, Early detection of sporadic pancreatic cancer: summative review, Pancreas, vol.44, issue.5, pp.693-712, 2015.

M. I. Canto, F. Harinck, and R. H. Hruban, International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer, Gut, vol.62, issue.3, pp.339-347, 2013.

, Guide ALD 30 -Cancer du pancreas, 2010.

M. Ducreux, T. Seufferlein, and J. Van-laethem, Systemic treatment of pancreatic cancer revisited, Seminars in Oncology, vol.46, issue.1, pp.28-38, 2019.

, Site de l'Union Internationale pour le Control du Cancer (UICC)

S. Kakar, AJCC Cancer Staging Manual, vol.8, pp.337-347, 2017.

A. De-devita, V. T. , L. Ts, S. A. Rosenberg, and H. Devita, Rosenberg Principles & practice of oncology 11th Edition, 2018.

G. R. Varadhachary, E. P. Tamm, and J. L. Abbruzzese, Borderline resectableau pancreatic cancer: definitions, management, and role of preoperative therapy, Ann Surg Oncol, vol.13, issue.8, pp.1035-1046, 2006.

M. A. Tempero, M. P. Malafa, and M. Al-hawary, Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Natl Compr Canc Netw, vol.15, pp.1028-1061, 2017.

B. Ren, X. Liu, and A. A. Suriawinata, Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: Histopathology, Cytopathology, and Molecular Pathology, Am J Pathol, vol.189, issue.1, pp.9-21, 2019.

, Fonds anticancer, guide ESMO pour les patients, vol.56, 2013.

C. S. Verbeke and K. V. Menon, Redefining resection margin status in pancreatic cancer, HPB (Oxford), vol.11, issue.4, pp.282-289, 2009.

M. Oken, R. Creech, and D. Tormey, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, vol.5, pp.649-655, 1982.

M. A. Tempero, M. P. Malafa, and M. Al-hawary, Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, vol.15, issue.8

M. Ducreux, C. Asa, and C. Caramella, Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.56-68, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01810223

J. Hopkins-medicine,

, Memorial Sloan Kettering Cancer Center

P. Onco,

V. P. Groot, G. Gemenetzis, and A. B. Blair, Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma, Ann Surg Oncol, vol.25, issue.8, pp.2475-2483, 2018.

D. , Institut National du Cancer. Les traitements du cancer du pancréas, collection Guides patients Cancer info, 2012.

H. A. Burris, M. J. Moore, and J. Andersen, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, vol.15, issue.6, pp.2403-2413, 1997.

V. Hoff, D. D. Ervin, T. Arena, and F. P. , Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, NEJM, vol.369, issue.18, pp.1691-1703, 2013.

T. Conroy, F. Desseigne, and M. Ychou, FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, NEJM, vol.364, issue.19, pp.1817-1825, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

D. Evans, American Society of Clinical Oncology Educational Book, vol.38, pp.300-305, 2018.

M. J. Bakens, L. G. Van-der-geest, and M. Van-putten, The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis, Cancer Med, vol.5, issue.10, pp.2825-2831, 2016.

M. D. Chuong, D. H. Boggs, and K. N. Patel, Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?, J Gastrointest Oncol, vol.5, issue.3, pp.166-177, 2014.

D. Lakomy-laboratoire-d'immunologie and C. Dijon, Académie de Besancon, 2015.

, Banque de schémas SVT Dijon Disponible

Y. Mellal, L'activation et la prolifération des lymphocytes T CD4+

J. Borst, T. Ahrends, and N. B?ba?a, CD4+ T cell help in cancer immunology and immunotherapy, Nat Rev Immunol, vol.18, pp.635-647, 2018.

. Espacesoignant and . Com, Les lymphocytes B et immunité à médiation humorale Disponible à

, Futura Science. Complémentarité Anticorps-antigène Disponible

D. S. Chen and I. Mellman, Oncology meets immunology : the cancer-immunology cycle, Immunity, 2013.

F. Pagès, J. Galon, and M. C. Dieu-nosjean, Immune infiltration in human tumors: a prognostic factor that should not be ignored, Oncogene, vol.29, issue.8, pp.1093-1102, 2010.

S. I. Grivennikov, F. R. Greten, and M. Karin, Immunity, inflammation, and cancer. Cell, vol.140, issue.6, pp.883-899, 2010.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, pp.646-674, 2011.

A. E. Karnoub and R. A. Weinberg, Chemokine networks and breast cancer metastasis, Breast Dis, vol.26, pp.75-85, 2006.

B. Z. Qian and J. W. Pollard, Macrophage diversity enhances tumor progression and metastasis, Cell, vol.141, issue.1, pp.39-51, 2010.

D. Hanahan and L. M. Coussens, Accessories to the crime: functions of cells recruited to the tumor microenvironment, Cancer Cell, vol.21, issue.3, pp.309-322, 2012.

G. Multhoff, M. Molls, and J. Radons, Chronic inflammation in cancer development, Front Immunol, vol.2, p.98, 2012.

S. Kruger, M. Ilmer, and S. Kobold, Advances in cancer immunotherapy 2019 -latest trends, J Exp Clin Cancer Res, vol.38, 2019.

D. M. Altmann, A Nobel prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens, Immunology, vol.155, issue.3, pp.283-287, 2018.

L. Aurisicchio and G. Ciliberto, Genetic cancer vaccines: current status and perspectives, Expert Opin Biol Th, vol.12, pp.1043-1058, 2012.

, Cancer Research Institute. Cancer Vaccines. Disponible à www.cancerresearch.org

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-264, 2012.

J. A. Marin-acevedo, B. Dholaria, and A. E. Soyano, Next generation of immune checkpoint therapy in cancer: new developments and challenges, J Hematol Oncol, vol.11, issue.1, p.39, 2018.

H. Johansson, R. Andersson, and M. Bauden, Immune checkpoint therapy for pancreatic cancer, World J Gastroenterol, vol.22, issue.43, pp.9457-9476, 2016.

L. Spain, S. Diem, and J. Larkin, Management of toxicities of immune checkpoint inhibitors, Cancer Treatment Reviews, vol.44, pp.51-60, 2016.

. Genscript,

S. Kruger, M. Ilmer, and S. Kobold, Advances in cancer immunotherapy 2019 -latest trends, J Exp Clin Cancer Res, vol.38, 2019.

C. Yee, The use of endogenous T cells for adoptive transfer, Immunological Reviews, vol.257, issue.1, pp.250-263, 2014.

D. W. Lee, B. D. Santomasso, and F. L. Locke, ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells, Biol Blood Marrow Transplant, vol.25, issue.4, pp.625-638, 2019.

, National Institute of Health, National Library of Medicine, Clinicaltrial.gov. Disponible à

, Meeting Library

L. H. Schwartz, S. Litière, and E. De-vries, RECIST 1.1-Update and clarification: From the RECIST committee, Eur J Cancer, vol.62, pp.132-137, 2016.

R. Royal, C. Levy, and K. Turner, Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma, J Immunother, vol.33, issue.8, pp.828-833, 2010.

D. T. Le, E. Lutz, and J. N. Uram, Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer, J Immunother, vol.36, issue.7, pp.382-389, 2013.

D. T. Le, E. Lutz, and L. Huang, Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer, 2012.

M. Aglietta, C. Barone, and M. B. Sawyer, A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer, Ann Oncol, vol.25, issue.9, pp.1750-1755, 2014.

P. Sharma, L. Dirix, D. Vos, and F. , Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma, JCO, vol.36, issue.4, pp.470-470, 2018.

E. M. O'reilly, D. Oh, and N. Dhani, Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial, JAMA Oncol, vol.5, issue.10, pp.1431-1438, 2019.

D. T. Le, T. S. Crocenzi, and J. N. Uram, Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR), JCO, vol.33, issue.15, pp.4148-4148, 2015.

A. C. Hopkins, M. Yarchoan, and J. N. Durham, T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma, JCI Insight, vol.3, issue.13, p.122092, 2018.

D. T. Le, T. S. Crocenzi, and J. N. Uram, Randomized Phase 2 study of the safety, efficacy and immune response of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). ASCO poster

Z. A. Wainberg, H. S. Hochster, and E. Kim, Phase I study of nivolumab (Nivo) + nabpaclitaxel (nab-P) + gemcitabine (Gem) in advanced pancreatic cancer (APC), JCO, vol.37, issue.4, pp.298-298, 2019.

I. Firdaus, D. Waterhouse, and M. Gutierrez, Nab-paclitaxel + Nivolumab +/-Gemcitabine in patients with advanced pancreatic cancer, 2016.

G. J. Weiss, J. Waypa, and L. Blaydorn, A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus), Br J Cancer, vol.117, issue.1, pp.33-40, 2017.

L. Diaz, A. Marabelle, and T. W. Kim, Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers, Annals of Oncology, vol.28, issue.5, pp.122-141, 2017.

. Le, E. Lutz, and L. Huang, Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer, Aduro Biotech. Engineered Immunotherapy for Cancer, 2012.

E. M. Jaffee, R. H. Hruban, and B. Biedrzycki, Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation, J Clin Oncol, vol.19, issue.1, pp.145-156, 2001.

E. Lutz, C. J. Yeo, and K. D. Lillemoe, A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation, Ann Surg, vol.253, issue.2, pp.328-335, 2011.

F. Ghiringhelli, C. Menard, and P. E. Puig, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol Immunother, vol.56, pp.641-649, 2007.

E. R. Lutz, A. A. Wu, and E. Bigelow, Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation, Cancer Immunol Res, vol.2, issue.7, pp.616-631, 2014.

D. T. Le, A. Wang-gillam, and V. Picozzi, Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer, J Clin Oncol, vol.33, issue.12, pp.1325-1333, 2015.

E. R. Lutz, A. A. Wu, and E. Bigelow, Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation, Cancer Immunol Res, vol.2, issue.7, pp.616-631, 2014.

K. S. Gunturu, G. R. Rossi, and M. W. Saif, Immunotherapy updates in pancreatic cancer: are we there yet ?, Ther Adv Med Oncol, vol.5, issue.1, pp.81-89, 2013.

G. R. Rossi, R. Lima, C. Hardacre, and J. M. , Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer, 2014.

J. M. Hardacre, M. Mulcahy, and W. Small, Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study, J Gastrointest Surg, vol.17, issue.1, pp.94-101, 2013.

, Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer Disponible à, 2016.

D. M. Geynisman, Y. Zha, and R. Kunnavakkam, A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma, J Immunother Cancer, vol.1, 2013.

B. T. Brett, S. C. Smith, and C. V. Bouvier, Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer, J Clin Oncol, vol.20, issue.20, pp.4225-4231, 2002.

A. D. Gilliam, P. Broome, and E. G. Topuzov, An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer, Pancreas, vol.41, issue.3, pp.374-379, 2012.

T. M. Nywening, A. Wang-gillam, and D. E. Sanford, Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectableau and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial, Lancet Oncol, vol.17, issue.5, pp.78-82, 2016.

M. Noel, E. M. O'reilly, and B. M. Wolpin, Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nabpaclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma, Invest New Drugs, pp.1-12, 2019.

N. Bahary, A. Wang-gillam, and S. Haraldsdottir, Phase 2 Trial of the IDO Pathway Inhibitor Indoximod Plus Gemcitabine/Nab-paclitaxel for the Treatment of Patients With Metastatic Pancreas cancer ASCO, 2018.

N. Bahary, I. Garrido-laguna, and P. Cinar, Phase 2 trial of the indoleamine2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of metastatic pancreas cancer:interimanalysisASCO, 2016.

G. L. Beatty, D. A. Torigian, and E. G. Chiorean, A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma, Clin Cancer Res, vol.19, issue.22, pp.6286-6295, 2013.

A. Inno, G. Lo-russo, and M. Salgarello, The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori, vol.104, pp.88-95, 2018.

L. Seymour, J. Bogaerts, and A. Perrone, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.20, issue.5, pp.30074-30082, 2017.

, New Drug Approval for Pembrolizumab

M. Hilmi, L. Bartholin, and C. Neuzillet, Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?, World J Gastroenterol, vol.24, issue.20, pp.2137-2151, 2018.

L. B. Alexandrov, S. Nik-zainal, and D. C. Wedge, Signatures of mutational processes in human cancer, 258. Imielinsk, Marcin, vol.502, pp.415-421, 2013.

D. T. Le, J. N. Durham, and K. N. Smith, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, issue.6349, pp.409-413, 2017.

M. ?uksza, N. Riaz, and V. Makarov, A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy, Nature, vol.551, issue.7681, pp.517-520, 2017.

V. P. Balachandran, M. ?uksza, and J. N. Zhao, Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature, vol.551, issue.7681, pp.512-516, 2017.

P. G. Natali, M. R. Nicotra, and A. Bigotti, Selective changes in expression of HLA class I polymorphic determinants in human solid tumors, Proc Natl Acad Sci U S A, vol.86, issue.17, pp.6719-6723, 1989.

B. Goeppert, L. Frauenschuh, and M. Zucknick, Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer, Br J Cancer, vol.113, pp.1343-1349, 2015.

E. Ryschich, T. Nötzel, and U. Hinz, Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma, Clin Cancer Res, vol.11, issue.2, pp.498-504, 2005.

P. Bonaventura, T. Shekarian, and V. Alcazer, Cold Tumors: A Therapeutic Challenge for, Immunotherapy. Front Immunol, vol.10, p.168, 2019.

R. M. Dallal, P. Christakos, K. Lee, S. Egawa, Y. Son et al., Paucity of dendritic cells in pancreatic cancer, Surgery, vol.131, issue.2, pp.135-138, 2002.

P. S. Hegde, V. Karanikas, and . Evers, The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition, Clin Cancer Res, pp.1865-1874, 2016.

P. Bonaventura, T. Shekarian, and V. Alcazer, Cold Tumors: A Therapeutic Challenge for, Immunotherapy. Front Immunol, vol.10, p.168, 2019.

E. D. Foucher, C. Ghigo, and S. Chouaib, Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment, Front Immunol, vol.9, p.1044, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02143543

M. Ducreux, T. Seufferlein, and J. L. Van-laethem, Systemic treatment of pancreatic cancer revisited, Seminars in Oncology, vol.46, issue.1, pp.28-38, 2019.

A. Neesse, C. A. Bauer, and D. Öhlund, Stromal biology and therapy in pancreatic cancer: ready for clinical translation?, Gut, vol.68, issue.1, pp.159-171, 2019.

S. Chouaib, M. Z. Noman, and K. Kosmatopoulos, Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer, Oncogene, vol.36, pp.439-445, 2017.

S. Gajiwala, A. Torgeson, and I. Garrido-laguna, Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle, J Gastrointest Oncol, vol.9, issue.6, pp.1014-1026, 2018.

. Eurekaalert, CD40 combination therapy can shrink pancreatic tumors Disponible à